At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Mar 2, 2026 at 19:00 ET
A cluster of insider transactions at Alnylam Pharmaceuticals over the past week includes open-market sales by the CSO and EVP of R&D totaling $204K, alongside non-cash grant and derivative exercise events involving top executives including the CEO and CFO. The sales are small in absolute value and represent a negligible fraction of the company's $43.4B market cap, while the other transactions are routine equity compensation activities.
- CSO Kevin Fitzgerald sold $91,483 in shares (289 shares at $316.55) on March 3, 2026
- EVP of R&D Pushkal Garg sold $112,443 in shares (355 shares at $316.74) on March 3, 2026
- CEO Yvonne Greenstreet received a non-cash award of 13,844 shares and exercised 5,921 shares via derivative on February 27 and March 2
- CFO Jeffrey Poulton and other C-suite executives received non-cash awards and exercised derivatives with no open-market impact
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access